INCA’s abstract Survey of Challenges in Access to Diagnostics and Treatment for Neuroendocrine Tumor (NET) Patients (SCAN) – Early Diagnosis and Treatment Availability has been accepted for poster presentation at the ESMO 22nd World Congress on Gastrointestinal Cancer. The Congress will be taking place virtually over the course of four days from July 1st to July 4th. All accepted abstracts will be available online for everyone interested in the field. The World Congress on Gastrointestinal Cancer is the biggest global forum to gather leading gastroenterology, oncology, pathology, and hepatology experts, clinicians, and surgeons, as well as clinical researchers from across the globe.
INCA will present the findings in an online poster, showcasing the global challenges in healthcare which patients living with gastro-pancreatic neuroendocrine tumor (GEP-NET) face today. This was made possible thanks to the 1670 GEP-NET patient participants in the SCAN survey, conducted by INCA in the end of 2019. SCAN data clearly outline the significant challenges GEP-NET patients face with early diagnosis globally. The survey findings call for an increase in the availability of NET diagnostics and treatment options, particularly newer, more specialized tools in order to improve early diagnosis. The presentation of the INCA survey results in front of the GI medical community is part of the effort to overcome the leading issue identified by NET patients via SCAN, namely that more healthcare professionals knowledgeable in NETs are needed.